Omnitrope 5mg – Sandoz 5mg/1.5ml x 5 vials
Omnitrope 5mg – Sandoz (Somatropin * 5mg/1.5ml x 5 vials )
Basic substance : Somatropin
Package : 5mg/1.5ml x 5 vials . Kit
Category : HGH
Omnitrope is a form of HGH used to treat growth failure in children and adults , and in those with chronic kidney failure or Noonan syndrome.
Omnitrope 5mg – Sandoz (Somatropin * 5mg/1.5ml x 5 vials )
Omnitrope (Somatropina) is a hormone that belongs to the group of peptides. It is secreted by the human pituitary under the action of a hypothalamic hormone called GH-RH. As its name says, its main function is to promote cell growth, regeneration and repair. It helps to activate the growth of bones, lean tissue, as well as the internal organs of the body. Thanks to it, the connective tissue constituting the tendinous, ligamentous and articular structures can repair itself and grow appropriately. But it is also involved in protein, carbohydrate, lipid, vitamin and mineral metabolism. It is for its different virtues, that this compound has been used successfully to cure cases of dwarfism by deficiency in GH. It is even used clinically to treat adults deficient in growth hormone exceptionally well. This miraculous molecule is nowadays one of the rejuvenating treatments, not to mention its very interesting use in some cases of wide burns.
The pack of Omnitrope 15 IU includes one glass cartridge of 5 mg/1.5 ml (15 IU) with the prefilled Somatropin solution. Usually, this cartridge is used with the Omnitrope Pen device that does not cause inconvenience during the doing the injection. Omnitrope is released by the well-known Sandoz company. Sandoz is an international pharmaceutical company which is based on the production of biosimilars and generics for the treatment of a large number of health problems.
Bodybuilders and high-level athletes are increasingly using the Omnitrope Pen to improve their athletic performance and physical abilities. Injections are done subcutaneously. It is however very important to change the injection site frequently, to avoid possible irritation. The pen should not be shaken very vigorously, which could damage the active molecule. Its use is usually intermittent, chaining 1 to 2 weeks of administration to an equal duration of leave and so on. Before stopping, the dosage should be lowered gradually, to avoid significant negative impacts. The usual medical dosage is 4 IU daily. In athletes, you can go up to 6 IU per day to administer at once or twice, in the morning and evening. Particular vigilance should be taken in people with diabetes, since this product disrupts the effectiveness of insulin. The purchase of Omnitrope online is an easy and very simple method.
Treatment with Omnitrope for short stature should be discontinued when the epiphyses are fused.
Pediatric Growth Hormone Deficiency (GHD)
Generally, a dosage of 0.16 to 0.24 mg/kg body weight /week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.
Prader-Willi Syndrome (PWS)
Generally, a dosage of 0.24 mg/kg body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.
Small for Gestational Age (SGA)
Generally, a dosage of up to 0.48 mg/kg body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.
Turner Syndrome (TS)
Generally, a dose of 0.33 mg/kg body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.
Idiopathic Short Stature (ISS)
Generally, a dose up to 0.47 mg/kg of body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.
Dosing of Adult Patients;
Adult Growth Hormone Deficiency (GHD)
Based on the weight-based dosing utilized in clinical studies with another somatropin product, the recommended dosage at the start of therapy is not more than 0.04 mg/kg/week given as a daily subcutaneous injection. The dose may be increased at 4- to 8-week intervals according to individual patient requirements to not more than 0.08 mg/kg/week. Clinical response, side effects, and determination of age- and gender-adjusted serum IGF-1 levels may be used as guidance in dose titration.
Alternatively, taking into account recent literature, a starting dose of approximately 0.2 mg/day (range, 0.15-0.30 mg/day) may be used without consideration of body weight. This dose can be increased gradually every 1 to 2 months by increments of approximately 0.1 to 0.2 mg/day, according to individual patient requirements based on the clinical response and serum IGF-1 concentrations. During therapy, the dose should be decreased if required by the occurrence of adverse events and/or serum IGF-1 levels above the age- and gender-specific normal range. Maintenance dosages vary considerably from person to person.
A lower starting dose and smaller dose increments should be considered for older patients, who are more prone to the adverse effects of somatropin than younger individuals. In addition, obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen. In order to reach the defined treatment goal, estrogen-replete women may need higher doses than men. Oral estrogen administration may increase the dose requirements in women.
Side effects :
Common side effects of Omnitrope include:
-injection site reactions (redness, soreness, swelling, rash, itching, -pain, or bruising),
-pain in your arms or legs,
-joint stiffness or pain, or
-cold symptoms such as stuffy nose, sneezing, sore throat.
-Tell your doctor if you have serious side effects of Omnitrope including:
severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, and weight loss;
sudden and severe pain behind your eyes, vision changes;
swelling in your head, face, hands, or feet; or
numbness or tingling in your wrist, hand, or fingers.
The Omnitrope dosage and administration schedule should be individualized based on the growth response of each patient, or the condition being treated. Omnitrope may interact with insulin or oral diabetes medicines, steroids, cyclosporine, seizure medication, birth control pills, or hormone replacement medications for men or women. Tell your doctor all medications and supplements you use. Omnitrope should be used only when prescribed during pregnancy. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Omnitrope (somatropin [rDNA origin] injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.